IPSC
insider transactionsCentury Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-23.4K
0 buy · 23.4K sell
Net value · 365d
-$57.8K
$0 in · $57.8K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
10
0 buy · 23.4K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Title: Chief Technology and M…
$5.8K
2.6K sh · $2.23
Own -1%
-
Sell·S
SVP Finance & Operations
$3.7K
1.7K sh · $2.23
Own -0%
-
Grant·A
Director
$0
74.0K sh
Own New
-
Grant·A
Director
$0
74.0K sh
Own New
-
Grant·A
Director
$0
74.0K sh
Own New
-
Grant·A
Director
$0
74.0K sh
Own New
-
Grant·A
Director
$0
74.0K sh
Own New
-
Grant·A
Director
$0
25.8K sh
Own New
-
Other·F
Chief Scientific Officer
$802
358 sh · $2.24
Own -0%
-
Other·F
President and CEO
$31.0K
13.8K sh · $2.24
Own -0%
-
Sell·S
Title: Chief Technology and M…
$1.1K
524 sh · $2.11
Own -0%
-
Sell·S
SVP Finance & Operations
$526
249 sh · $2.11
Own -0%
-
Other·F
President and CEO
$986
463 sh · $2.13
Own -0%
-
Other·F
President and CEO
$72.9K
31.2K sh · $2.34
Own -1%
-
Sell·S
SVP Finance & Operations
$618
264 sh · $2.34
Own -0%
-
Other·F
Chief Scientific Officer
$3.0K
1.4K sh · $2.19
Own -0%
-
Sell·S
Title: Chief Technology and M…
$25.7K
10.1K sh · $2.55
Own -2%
-
Sell·S
SVP Finance & Operations
$18.0K
7.0K sh · $2.55
Own -1%
-
Other·F
Chief Scientific Officer
$3.9K
1.4K sh · $2.73
Own -0%
-
Other·F
President and CEO
$151.2K
55.4K sh · $2.73
Own -1%
-
Sell·S
Title: Chief Technology and M…
$1.2K
479 sh · $2.54
Own -0%
-
Sell·S
SVP Finance & Operations
$626
247 sh · $2.54
Own -0%
-
Other·F
President and CEO
$1.2K
463 sh · $2.56
Own -0%
-
Other·F
President and CEO
$54.6K
31.2K sh · $1.75
Own -1%
-
Sell·S
SVP Finance & Operations
$589
323 sh · $1.82
Own -0%
-
Grant·A
Chief Scientific Officer
$0
265.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
135.0K sh
Own +13%
-
Grant·A
President and CEO
$0
945.0K sh
Own New
-
Grant·A
President and CEO
$0
475.0K sh
Own +14%
-
Grant·A
Title: Chief Technology and M…
$0
265.0K sh
Own New
-
Grant·A
Title: Chief Technology and M…
$0
135.0K sh
Own +35%
-
Grant·A
SVP Finance & Operations
$0
225.0K sh
Own New
-
Grant·A
SVP Finance & Operations
$0
110.0K sh
Own +27%
-
Other·F
Chief Scientific Officer
$1.6K
1.6K sh · $1.00
Own -0%
-
Grant·A
Director
$0
88.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Gregory Russotti | Sell S | 2.6K | $5.8K |
| Jun 12, 2026 | Douglas Carr | Sell S | 1.7K | $3.7K |
| Jun 11, 2026 | Martin Patrick Murphy | Grant A | 74.0K | $0 |
| Jun 11, 2026 | Han Myung Lee | Grant A | 74.0K | $0 |
| Jun 11, 2026 | Alessandro Riva | Grant A | 74.0K | $0 |
| Jun 11, 2026 | Daphne Quimi | Grant A | 74.0K | $0 |
| Jun 11, 2026 | Kimberly Blackwell | Grant A | 74.0K | $0 |
| Jun 11, 2026 | Kimberly Blackwell | Grant A | 25.8K | $0 |
| Jun 11, 2026 | Chad Cowan | Other F | 358 | $802 |
| Jun 11, 2026 | Brent Pfeiffenberger KEY | Other F | 13.8K | $31.0K |
| Jun 8, 2026 | Gregory Russotti | Sell S | 524 | $1.1K |
| Jun 8, 2026 | Douglas Carr | Sell S | 249 | $526 |
| Jun 5, 2026 | Brent Pfeiffenberger KEY | Other F | 463 | $986 |
| May 15, 2026 | Brent Pfeiffenberger KEY | Other F | 31.2K | $72.9K |
| May 4, 2026 | Douglas Carr | Sell S | 264 | $618 |
| Apr 1, 2026 | Chad Cowan | Other F | 1.4K | $3.0K |
| Mar 12, 2026 | Gregory Russotti | Sell S | 10.1K | $25.7K |
| Mar 12, 2026 | Douglas Carr | Sell S | 7.0K | $18.0K |
| Mar 11, 2026 | Chad Cowan | Other F | 1.4K | $3.9K |
| Mar 11, 2026 | Brent Pfeiffenberger KEY | Other F | 55.4K | $151.2K |
| Mar 9, 2026 | Gregory Russotti | Sell S | 479 | $1.2K |
| Mar 9, 2026 | Douglas Carr | Sell S | 247 | $626 |
| Mar 6, 2026 | Brent Pfeiffenberger KEY | Other F | 463 | $1.2K |
| Feb 13, 2026 | Brent Pfeiffenberger KEY | Other F | 31.2K | $54.6K |
| Feb 3, 2026 | Douglas Carr | Sell S | 323 | $589 |
| Feb 2, 2026 | Chad Cowan | Grant A | 265.0K | $0 |
| Feb 2, 2026 | Chad Cowan | Grant A | 135.0K | $0 |
| Feb 2, 2026 | Brent Pfeiffenberger KEY | Grant A | 945.0K | $0 |
| Feb 2, 2026 | Brent Pfeiffenberger KEY | Grant A | 475.0K | $0 |
| Feb 2, 2026 | Gregory Russotti | Grant A | 265.0K | $0 |
| Feb 2, 2026 | Gregory Russotti | Grant A | 135.0K | $0 |
| Feb 2, 2026 | Douglas Carr | Grant A | 225.0K | $0 |
| Feb 2, 2026 | Douglas Carr | Grant A | 110.0K | $0 |
| Jan 2, 2026 | Chad Cowan | Other F | 1.6K | $1.6K |
| Dec 9, 2025 | Martin Patrick Murphy | Grant A | 88.0K | $0 |
About IPSC insider trading
This page tracks insider transactions for Century Therapeutics, Inc. (IPSC) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.